Iris Biotechnologies Announces That the Japanese Patent Office Has Issued a Notice of Allowance of Its Key Patent Application – Artificial Intelligence System for Genetic Analysis

SANTA CLARA, Calif.–(BUSINESS WIRE)–Iris Biotechnologies announces that the Japanese Patent Office has
issued a notice of allowance of its Artificial Intelligence System for
Genetic Analysis to be granted as a patent. This follows the issuance of
a family of patents in the US, EU, Canada, Hong Kong, Australia, and New
Zealand.
A critical mass of scientific knowledge, instrumentation and affordable
computing power is at hand, yet a critical piece has been missing which
Iris is now able to provide: smart integration of genomic, proteomic,
lifestyle, family history and environmental information. Iris is poised
to play a leading role in answering the unmet needs of a
multi-billion-dollar market.
“Compared to when Iris Biotechnologies common stock (IRSB) was trading
at $4.50 per share, the Company now has more patents worldwide and is
planning to launch the first Iris Wellness Labs this summer,” said Iris
CEO Simon Chin. To read more about Iris Wellness services, please visit
ir.irisbiotech.com under Quick Links.
About Iris Biotechnologies Inc.
Iris Biotechnologies Inc. (OTC MKTS: IRSB), unlike other life sciences
companies, focuses on providing accurate, affordable precision
healthcare through comprehensive analysis of the whole person inside and
out. Iris offers the best approach to the treatment of cancer and other
diseases through incorporating DNA, RNA and protein analysis with a
patient’s medical records, family medical history, life style and
environmental exposures. Iris enables personalized, cost-effective
healthcare and is the future of precision medicine.
Forward-looking Statements
Statements in this presentation about the Company’s expectations,
applications of its technology, markets, launch of tests and other
statements that are not historical facts are “forward-looking
statements” within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934 and are
based on management’s current beliefs, assumptions, estimates and
projections. Actual results may differ materially from those projected
in the forward-looking statements for various reasons, including risks
associated with product and test development, test transfer to
contracting labs, government regulation, market acceptance, limited
commercial experience, dependence on key personnel, obtaining financing
and other factors discussed in the Company’s periodic reports filed with
the Securities and Exchange Commission.